CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of ovarian cancer.
  
  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with ovarian cancer.
  
  LEARNING OBJECTIVES

  • Understand clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced OC, and provide appropriate counsel regarding personalized treatment recommendations.
  • Evaluate the biological rationale for and published clinical research data with PARP inhibitors in combination with other systemic therapies, and consider the implications of these findings for OC management.
  • Appraise biological and patient- and treatment-related factors to individualize the selection and sequencing of therapy for platinum-sensitive and platinum-resistant recurrent OC.
  • Assess clinical trial data with and newly adapted indications for FDA-endorsed PARP inhibitors for recurrent, platinum-sensitive and multiregimen-refractory OC, and optimally incorporate these agents into management algorithms.
  • Discern the rationale for targeting folate receptor alpha in OC, determine optimal methods to test for this newly relevant biomarker and evaluate the role of novel approaches to exploit it in clinical practice.
  • Appreciate the side effects associated with various commonly used systemic therapies for OC.
  • Recall the designs of ongoing clinical trials evaluating novel agents and strategies for OC, and counsel patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
  
  CREDIT DESIGNATION STATEMENT
  Video Program: This educational activity for 1.75 contact hours is provided by RTP during the period of June 2024 to June 2025.
  
  This activity is awarded 1.75 ANCC pharmacotherapeutic contact hours.
  
  ONCC/ILNA CERTIFICATION INFORMATION
  The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2024/OvarianCancer/ILNA.
  
  ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
  
  PRIVACY POLICY 
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. 
  
  FOR SUCCESSFUL COMPLETION
  Video Program: This NCPD activity consists of a video component. To receive credit, the participant should review the NCPD information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ONS2024/Ovarian/Video/NCPD.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Courtney Arn, CNP
  The James Cancer Hospital and Solove Research Institute
  The Ohio State University
  Columbus, Ohio
  
  Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Eisai Inc, Genmab US Inc, ImmunoGen Inc, Merck, Seagen Inc.
  
  Floor J Backes, MD
  Professor
  Fellowship Director
  Division of Gynecologic Oncology
  Department of Obstetrics and Gynecology
  The Ohio State University College of Medicine
  The James Cancer Hospital and Solove Research Institute
  Columbus, Ohio
  
  Advisory Committees and Consulting Agreements: AstraZeneca Pharmaceuticals LP, BioNTech SE, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, GSK, ImmunoGen Inc, Merck.
  
  Kathleen N Moore, MD, MS
  Deputy Director
  Associate Director, Clinical Research
  Virginia Kerley Cade Chair in Developmental Therapeutics
  Co-Director, Cancer Therapeutics Program
  Stephenson Cancer Center at the University of Oklahoma HSC
  Associate Director, GOG Partners
  Board of Directors, GOG Foundation
  Oklahoma City, Oklahoma
  
  Advisory Committees: Aadi Bioscience, Aravive Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Caris Life Sciences, Clovis Oncology, Duality Biologics, Eisai Inc, Genentech, a member of the Roche Group, GSK, ImmunoGen Inc, Janssen Biotech Inc, Lilly, Merck, Mersana Therapeutics Inc, Myriad Genetic Laboratories Inc, Panavance Therapeutics, Regeneron Pharmaceuticals Inc, VBL Therapeutics, Verastem Inc, Zentalis Pharmaceuticals; Consulting Agreements: Aadi Bioscience, Caris Life Sciences, Duality Biologics, Eisai Inc, Mersana Therapeutics Inc, Regeneron Pharmaceuticals Inc; Contracted Research: Genentech, a member of the Roche Group, GSK, Lilly, PTC Therapeutics.
  
  Jaclyn Shaver, MS, APRN, CNP, WHNP
  Section of Gynecologic Oncology
  Stephenson Cancer Center
  OU Health
  Oklahoma City, Oklahoma
  
  No relevant conflicts of interest to disclose.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, and Merck.
  
  Release date: June 2024
  Expiration date: June 2025
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.